Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$36.05 -1.0%	$39.91	$26.20 ▼ $63.50	$1.66B	1.43	740,884 shs	239,069 shs
DYN Dyne Therapeutics	$11.96 -2.3%	$10.37	$6.36 ▼ $47.39	$1.70B	1.08	2.63 million shs	1.15 million shs
IMCR Immunocore	$32.55 +0.6%	$33.45	$23.15 ▼ $39.33	$1.64B	0.77	337,334 shs	437,921 shs
PRTA Prothena	$8.52 0.0%	$6.62	$4.32 ▼ $22.83	$458.47M	-0.03	1.06 million shs	510,737 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-1.33%	-0.79%	-7.38%	-9.38%	-27.24%
DYN Dyne Therapeutics	-0.65%	+5.42%	+35.81%	+4.17%	-73.44%
IMCR Immunocore	+0.09%	+1.47%	-10.93%	+2.15%	-12.33%
PRTA Prothena	-0.12%	+13.00%	+36.10%	+24.93%	-59.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APGE Apogee Therapeutics	3.5679 of 5 stars	4.4	3.0	1.6	4.2	0.0
DYN Dyne Therapeutics	3.2958 of 5 stars	4.5	1.0	1.4	5.0	0.0
IMCR Immunocore	1.957 of 5 stars	3.3	1.0	2.8	2.5	0.0
PRTA Prothena	3.2716 of 5 stars	4.2	4.0	1.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.86	Moderate Buy	$99.00	174.60% Upside
DYN Dyne Therapeutics	3.00	Buy	$33.80	182.51% Upside
IMCR Immunocore	2.50	Moderate Buy	$58.00	78.19% Upside
PRTA Prothena	2.33	Hold	$30.25	255.17% Upside

Current Analyst Ratings Breakdown

Latest PRTA, APGE, IMCR, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	APGE Apogee Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
8/5/2025	PRTA Prothena	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$18.00 ➝ $10.00
8/5/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/5/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.43 per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$4.02 per share	N/A
IMCR Immunocore	$356.15M	4.61	N/A	N/A	$7.71 per share	4.22
PRTA Prothena	$135.16M	3.39	N/A	N/A	$6.03 per share	1.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$4.13	N/A	N/A	N/A	N/A	-34.65%	-32.76%	N/A
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	N/A
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)
PRTA Prothena	-$122.31M	-$5.64	N/A	N/A	N/A	-2,929.30%	-62.17%	-54.43%	N/A

Latest PRTA, APGE, IMCR, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.03	-$1.13	-$0.10	-$1.13	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
8/4/2025	Q2 2025	PRTA Prothena	-$1.11	-$1.86	-$0.75	-$2.34	$5.36 million	$4.42 million
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.36	16.36
DYN Dyne Therapeutics	0.17	16.83	16.83
IMCR Immunocore	1.01	5.89	5.86
PRTA Prothena	N/A	5.68	5.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
DYN Dyne Therapeutics	96.68%
IMCR Immunocore	84.50%
PRTA Prothena	97.08%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
DYN Dyne Therapeutics	20.77%
IMCR Immunocore	10.40%
PRTA Prothena	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.11 million	26.39 million	Optionable
DYN Dyne Therapeutics	100	142.26 million	112.72 million	Optionable
IMCR Immunocore	320	50.39 million	45.15 million	Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable

PRTA, APGE, IMCR, and DYN Headlines

Recent News About These Companies

Analysts Set Prothena Corporation plc (NASDAQ:PRTA) Price Target at $30.25

August 17 at 2:17 AM | americanbankingnews.com

Prothena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Hold" from Analysts

August 15, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?

August 14, 2025 | marketbeat.com

Citizens JMP Remains a Buy on Prothena (PRTA)

August 9, 2025 | theglobeandmail.com

FY2026 EPS Estimates for Prothena Lifted by Chardan Capital

August 9, 2025 | marketbeat.com

Cantor Fitzgerald Increases Earnings Estimates for Prothena

August 8, 2025 | marketbeat.com

FY2025 EPS Estimates for Prothena Reduced by HC Wainwright

August 8, 2025 | marketbeat.com

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful

August 7, 2025 | msn.com

Prothena (NASDAQ:PRTA) Price Target Cut to $10.00 by Analysts at Royal Bank Of Canada

August 6, 2025 | marketbeat.com

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

August 6, 2025 | businesswire.com

Prothena's (PRTA) Buy Rating Reiterated at HC Wainwright

August 6, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Given "Buy" Rating at Chardan Capital

August 6, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Announces Earnings Results, Misses Expectations By $0.80 EPS

August 5, 2025 | marketbeat.com

9 Analysts Assess Prothena Corp: What You Need To Know

August 5, 2025 | benzinga.com

Prothena Reports Q2 2025 Financial Results and Pipeline Progress

August 4, 2025 | tipranks.com

Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

August 4, 2025 | zacks.com

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

August 4, 2025 | businesswire.com

Prothena Corporation plc (NASDAQ:PRTA) Shares Purchased by DCF Advisers LLC

August 4, 2025 | marketbeat.com

Federated Hermes Inc. Sells 199,922 Shares of Prothena Corporation plc (NASDAQ:PRTA)

August 3, 2025 | marketbeat.com

A Glimpse of Prothena Corp's Earnings Potential

August 2, 2025 | benzinga.com

Prothena Secures Leadership with New Executive Agreements

July 31, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA, APGE, IMCR, and DYN Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$36.05 -0.36 (-0.98%)

Closing price 03:59 PM Eastern

Extended Trading

$36.03 -0.02 (-0.06%)

As of 04:10 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$11.96 -0.29 (-2.33%)

Closing price 03:59 PM Eastern

Extended Trading

$12.16 +0.20 (+1.64%)

As of 04:10 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Immunocore NASDAQ:IMCR

$32.55 +0.21 (+0.65%)

Closing price 03:59 PM Eastern

Extended Trading

$32.47 -0.08 (-0.25%)

As of 04:10 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Prothena NASDAQ:PRTA

$8.52 0.00 (-0.04%)

Closing price 03:59 PM Eastern

Extended Trading

$8.48 -0.04 (-0.43%)

As of 04:10 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time